News
ORP-101 has been shown in preclinical studies to not cross the blood-brain barrier. ORP-101 successfully completed Phase 1 clinical trials and was granted FDA Fast Track designation in 2018.
OrphoMed, Inc. announces presentation of Phase 1 data at Digestive Disease Week®, May 4, 2020 at 12:30 p.m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback